Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

Background: Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI. Methods: Metastatic NSCLC patients underwent a nutritional assessment prior...

Full description

Bibliographic Details
Main Authors: Pascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, Jean-Philippe Durand, Elizabeth Fabre, Sixtine De Percin, Clémentine Vaquin Villeminey, Anne-Catherine Piketty, Nathalie Rassy, Guillaume Ulmann, Diane Damotte, Audrey Mansuet-Lupo, Frédérique Giraud, Marco Alifano, Marie Wislez, Jérôme Alexandre, Anne Jouinot, François Goldwasser
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:EBioMedicine
Subjects:
Immunotherapy
Cachexia
Non-small cell lung cancer
Basal metabolism
Energy expenditure
Progression-free survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421004230

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421004230

Similar Items